Compare IDEXX Laboratories, Inc. (IDXX) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Invesco Ltd. — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Invesco Ltd. trades at $29.51 (market cap $13.28B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3× Invesco Ltd.'s market cap, and Invesco Ltd. pays a 2.86% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Invesco Ltd. for 77 Days on average.
| IDXX | IVZ | |
|---|---|---|
Market Cap | $40.43B | $13.28B |
Volume | 692,164 | 3,698,033 |
Sector | Health | Financials |
52-Week High | $766.68 | $33.31 |
52-Week Low | $504.70 | $22.44 |
Typical Hold Time | 46 Days | 77 Days |
Enterprise Value | $41.32B | $23.45B |
Dividend Yield | — | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
IVZ trades at $30.09, down 1.34% on the day, with a bearish technical signal and mixed earnings history. The company reported a net loss of $281.70 million for 2025, though revenue grew to $6.38 billion. Analyst consensus is a $33.71 price target with no sell ratings, but technical indicators and recent negative profit margins highlight near-term challenges.
The outlook is cautious; while analyst support and a dividend provide some stability, persistent negative profitability and bearish technicals suggest limited upside until earnings improve. Key risks include execution on turning profits positive and market-sensitive revenue streams.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
